There are a couple of ways for RACE to potentially partner that could support (or not hinder) a buyout transaction:
I personally prefer #1 as it keeps the competition wide open for a future buyout by a Big Pharma for the US/Europe revenue opportunity which Big Pharma focus on.
- RACE could license/partner for specific geographic regions in way that excludes US/Europe. A licensing deal sets an anchor for pricing of the treatment. That builds sentiment, credibility and value of RACE in the eyes of the market. It's a way to bring in cash from milestone payments whilst RACE build clinical maturity for a bigger fish to bite.
- RACE could partner with a future buyer for future milestone payments and this would then be a stepping stone to a buyout.
Speculative M&A Transaction Analysis, page-592
-
- There are more pages in this discussion • 263 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |